Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Healthtrust
Deloitte
Boehringer Ingelheim
Harvard Business School
Fish and Richardson
Queensland Health
Argus Health

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEGARELIX ACETATE

« Back to Dashboard

Clinical Trials for Degarelix Acetate

Trial ID Title Status Sponsor Phase Summary
NCT00215683 An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer Completed Ferring Pharmaceuticals Phase 2/Phase 3 This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years (including one year in the main study).
NCT00946920 A Trial of Degarelix in Patients With Prostate Cancer Completed Ferring Pharmaceuticals Phase 3 A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
NCT01220869 A Study of Degarelix in Taiwanese Patients With Prostate Cancer Completed Ferring Pharmaceuticals Phase 3 A phase III trial investigating the efficacy and safety of degarelix one-month depot in Taiwanese patients with prostate cancer.
NCT01242748 A Degarelix Trial in Patients With Prostate Cancer Terminated Ferring Pharmaceuticals Phase 3 A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.
NCT01309672 S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Active, not recruiting National Cancer Institute (NCI) Phase 2 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.
NCT01309672 S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Active, not recruiting Southwest Oncology Group Phase 2 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.
NCT01344564 Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide Completed Ferring Pharmaceuticals N/A The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without a rise in serum testosterone. The investigators expect testosterone will quickly and reliably reach castrate levels after initiation of ADT and will remain castrate during the transition, and there will be no "testosterone surge" after leuprolide injection.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Degarelix Acetate

Condition Name

Condition Name for Degarelix Acetate
Intervention Trials
Prostate Cancer 12
Stage III Prostate Cancer 4
Stage IV Prostate Cancer 3
Stage IIA Prostate Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Degarelix Acetate
Intervention Trials
Prostatic Neoplasms 19
Adenocarcinoma 6
Neoplasm Metastasis 1
Bone Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Degarelix Acetate

Trials by Country

Trials by Country for Degarelix Acetate
Location Trials
United States 75
Canada 6
Mexico 4
Belgium 3
Netherlands 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Degarelix Acetate
Location Trials
Washington 5
Maryland 4
Michigan 4
Texas 4
Colorado 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Degarelix Acetate

Clinical Trial Phase

Clinical Trial Phase for Degarelix Acetate
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 1
Phase 2 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Degarelix Acetate
Clinical Trial Phase Trials
Recruiting 7
Completed 5
Active, not recruiting 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Degarelix Acetate

Sponsor Name

Sponsor Name for Degarelix Acetate
Sponsor Trials
National Cancer Institute (NCI) 6
Ferring Pharmaceuticals 6
Sidney Kimmel Comprehensive Cancer Center 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Degarelix Acetate
Sponsor Trials
Other 30
Industry 10
NIH 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
McKesson
Farmers Insurance
US Department of Justice
Medtronic
US Army
Federal Trade Commission
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.